Grifols GRFS
NASDAQ GRFS
$8.00 +0.01 (+0.13%)
At close: Aug 21, 2026 · 4:00 PM EDT

Grifols (GRFS) Income from Non-Controlling Interests (2010 - 2023)

Grifols' (GRFS) quarterly Income from Non-Controlling Interests came in at $130569.6 in Q4 2023, up 103.57% YoY from $64139.9 in Q4 2022, and up 103.57% on a QoQ basis from $64139.9 in Q4 2022.

Grifols (GRFS) Income from Non-Controlling Interests (2010 - 2023) Analysis & Trends

Grifols (GRFS) has 13 years of Income from Non-Controlling Interests data on file, last reported at $130569.6 in Q4 2023.

  • Quarterly Income from Non-Controlling Interests rose 103.57% year-over-year to $130569.6 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was -$18.6 million (down 11.57% YoY) and the FY2025 annual result came in at $114.1 million, up 90.63% from the prior year.
  • Income from Non-Controlling Interests advanced to $130569.6 in Q4 2023, from $64139.9 in the prior quarter.
  • In the past five years, Income from Non-Controlling Interests ranged from a high of $130569.6 in Q4 2023 to a low of -$18.9 million in Q1 2020.
  • A 4-year average of -$4.7 million and a median of $82649.9 in 2019 frame the typical range for Income from Non-Controlling Interests.
  • Annual changes were most pronounced in 2019 — Income from Non-Controlling Interests soared 115.33% — and 2020, when it sank 18826.37%.
  • Tracing GRFS's Income from Non-Controlling Interests over 4 years: stood at $101160.0 in 2019, then slumped by 18826.37% to -$18.9 million in 2020, then jumped by 100.34% to $64139.9 in 2022, then jumped by 103.57% to $130569.6 in 2023.
  • The last three Income from Non-Controlling Interests figures came in at $130569.6 (Q4 2023), $64139.9 (Q4 2022), and -$18.9 million (Q1 2020), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Inc. Minority (Qtr)
1 Johnson & Johnson 652.20 Bn 631.44 Bn 17.26 Bn -
2 AbbVie 469.51 Bn 462.94 Bn 12.70 Bn 3.00 Mn
3 Merck 376.81 Bn 369.67 Bn 12.21 Bn -2.00 Mn
4 Novartis Ag 303.04 Bn 295.35 Bn 11.24 Bn -7.00 Mn
5 Astrazeneca 257.61 Bn 252.71 Bn 12.86 Bn 1.00 Mn
6 Amgen 237.37 Bn 223.38 Bn 7.24 Bn -
7 Gilead Sciences 181.73 Bn 178.55 Bn 6.22 Bn -
8 Pfizer 159.66 Bn 147.96 Bn 10.94 Bn 10.00 Mn
9 Gsk 106.24 Bn 102.07 Bn 8.24 Bn 741.95 Mn
10 Grifols 5.45 Bn 4.45 Bn - -

Historic Data

Download Data
DateValue
Dec 31, 2023 130,569.61
Dec 31, 2022 64,139.89
Mar 31, 2020 -18.94 Mn
Mar 31, 2019 101,159.97
Dec 31, 2018 2.06 Mn
Jun 30, 2018 668,328.87
Mar 31, 2018 -659,722.11
Dec 31, 2017 -1.22 Mn
Jun 30, 2017 256,194.99
Mar 31, 2017 -274,874.98
Dec 31, 2016 -353,069.82
Sep 30, 2016 256,722.43
Jun 30, 2016 325,404.01
Dec 31, 2015 -1.98 Mn
Sep 30, 2015 201,323.57
Jun 30, 2015 -278,495.60
Mar 31, 2015 -754,728.11
Dec 31, 2014 833,638.93
Sep 30, 2014 848,139.23
Jun 30, 2014 721,604.52